Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals
Brendan J Nolan, Shalem Y Leemaqz, Olivia Ooi, Pauline Cundill, Nicholas Silberstein, Peter Locke, Mathis Grossmann, Jeffrey D Zajac, Ada S Cheung
INTERNAL MEDICINE JOURNAL | WILEY | Published : 2021
BACKGROUND: Masculinising hormone therapy with testosterone is used to align an individual's physical characteristics with his or her gender identity. Testosterone therapy is typically administered via intramuscular or transdermal routes, and polycythaemia is the most common adverse event. AIMS: To compare the risk of polycythaemia with different formulations of testosterone therapy in transmasculine individuals. METHODS: A retrospective cross-sectional analysis was undertaken of transmasculine individuals at a primary and secondary care clinic in Melbourne, Australia. A total of 180 individuals who were on testosterone therapy for >6 months was included. Groups included those receiving: (i)..View full abstract
Related Projects (1)
Awarded by Australian Government National Health and Medical Research Council Early Career Fellowship
B. J. Nolan is supported by the Royal Australasian College of Physicians Fellows Research Entry Scholarship. A. S. Cheung is supported by an Australian Government National Health and Medical Research Council Early Career Fellowship (#1143333) and receives research support from the Viertel Charitable Foundation Clinical Investigator Award, Endocrine Society of Australia Postdoctoral Award and the Royal Australasian College of Physicians Vincent Fairfax Family Foundation.